Bruce Cozadd - Jazz Pharmaceuticals Insider

Jazz Pharmaceuticals Public Limited Company -- Germany Stock  

EUR 121.00  3.00  2.42%

Chairman of the Board, CEO

Mr. Bruce C. Cozadd is a Chairman of the Board, Chief Executive Officer of Jazz Pharmaceuticals PLC. He has served as our Chairman and Chief Executive Officer since the closing of the Azur Merger in January 2012. He cofounded Jazz Pharmaceuticals, Inc. and has served as Chairman and Chief Executive Officer of Jazz Pharmaceuticals, Inc. since April 2009. From 2003 until 2009, he served as Jazz Pharmaceuticals, Inc.s Executive Chairman and as a member of its board of directors. From 1991 until 2001, he held various positions with ALZA Corporationrationration, a pharmaceutical company acquired by Johnson Johnson, most recently as Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporationrationration, he held the roles of Chief Financial Officer and Vice President, Corporationrationrate Planning and Analysis. He serves on the boards of directors and compensation committees of Cerus Corporationrationration, a biomedical products company, and Threshold Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, and on the boards of The Nueva School, a nonprofit organization, and SFJAZZ, a nonprofit organization. He received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. As our Chief Executive Officer, he brings to our board of directors a detailed knowledge of our business.
Age: 52  Chairman Since 2009  MBA    
353 1 634 7800

Bruce Cozadd Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.05 % which means that it generated profit of $8.05 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 17.79 % meaning that it generated $17.79 on every $100 dollars invested by stockholders.
The company has accumulated 1.58 B in total debt with debt to equity ratio (D/E) of 63.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Jazz Pharmaceuticals Public Limited Company has Current Ratio of 3.04 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Entity Summary

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with Parkinsons disease Vyxeos for high-risk acute myeloid leukemia and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. Jazz Pharmaceuticals is traded on Frankfurt Stock Exchange in Germany.Jazz Pharmaceuticals Public Limited Company (J7Z) is traded on Frankfurt Stock Exchange in Germany. It is located in Connaught House and employs 1,140 people.

Did you try this?

Run Portfolio Suggestion Now

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
Hide  View All  NextLaunch Portfolio Suggestion
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Jazz Pharmaceuticals Public Limited Company to your portfolio

Top Management

Jazz Pharmaceuticals Leadership Team
Matthew Young, President, MBA
Paul Berns, Director
Iain McGill, President
Daniel Swisher, President, MBA
Suzanne Hooper, President
Rick Winningham, Director, MBA
Peter Gray, Director
Heather McSharry, Director
Michael Miller, President, MBA
Katherine Littrell, President
Paul Treacy, President
Patrick Enright, Director, MBA
Karen Wilson, President
Norbert Riedel, Director, Ph.D
Seamus Mulligan, Director
Russell Cox, President
Catherine Sohn, Director
Karen Smith, Executive, MBA
Elmar Schnee, Director
Kenneth OKeefe, Director, MBA
Bruce Cozadd, Chairman, MBA

Stock Performance

Jazz Pharmaceuticals Performance Indicators